Riferimenti bibliografici
1. Carosi G et al. Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop. Dig Liver Dis. 2011;43(4):259-65.
2. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50(2):227-242.
3. Buster EH et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology. 2009;137(6):2002-9.
4. Marcellin P et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359(23):2442-55.
5. Tenney DJ et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology. 2009;49(5):1503-14.
6. Lampertico P. Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice. J Hepatol. 2009;50(4):644-7.
7. Woo G et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology. 2010;139(4):1218-29.
8. Liaw YF et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011;53(1):62-72.
9. Garg H et al. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology. 2011;53(3):774-80.
10. Heathcote EJ et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011;140(1):132-43.
11. Lampertico P et al. EASL 2011, Poster 731.
12. Lampertico P et al. AASLD 2010, Poster 391.
13. Snow-Lampart A et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology.2011;53(3):763-73.
14. Suzuki F et al. Selection of a virus strain resistant to entecavir in a nucleoside-naïve patient with hepatitis B of genotype H. J Clin Virol. 2007;39(2):149-52.
15. Guo JJ et al. Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naïve patient. Antiviral Res. 2009;81(2):180-3.
16. Mirandola S et al. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B. J Viral Hepat. 2011;18(7):e212-6.
17. Berg T et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology. 2010;139(4):1207-17.
18. Dakin H et al. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Value Health. 2010;13(8):934-45.
19. Colombo GL et al. A cost-effectiveness analysis of different therapies in patients with chronic hepatitis N in Italy. ClinicoEconomics and Outcomes Research. 2011;3:1-10.